Franzoi, Maria Alice
Vandeputte, Caroline
Eiger, Daniel
Caparica, Rafael
Brandão, Mariana
De Angelis, Claudia
Hendlisz, Alain
Awada, Ahmad
Piccart, Martine
de Azambuja, Evandro
Article History
Received: 21 January 2020
Accepted: 24 March 2020
First Online: 3 April 2020
Compliance with ethical standards
:
: MAF, CV, AH and CDA: none. DE: Funding for his ESMO fellowship: Novartis. RC: speaker honoraria from Boehringer Ingelheim, AstraZeneca and Janssen, travel grants from AstraZeneca and Pfizer. MB: travel grant and speaker honoraria from Roche/GNE. AA: Advisory role, speaker fees and research funding for his institute from: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma. M.P.: Board Member (Scientific Board): Oncolytics, Radius; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics; Research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon; Speakers bureau/stock ownership: none. EA: honoraria and advisory board: Roche/GNE, Novartis, Seatle Genetics; travel grants: Roche/GNE, GSK/Novartis; co-principal investigator of the LORELEI trial (NCT02273973). Research grant for his institute: Roche/GNE, Astra-Zeneca, Novartis, and Servier.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This study was approved by an internal ethics committee (EC3048), and informed consent was not required as patient’s information was retrieved from retrospective review of medical records only. The identity of the patients was kept always anonymously.